Please ensure Javascript is enabled for purposes of website accessibility

Why Norwegian Cruise Line Holdings, Carnival Corporation, and Royal Caribbean Stocks All Slumped Today

By Rich Smith – Sep 9, 2020 at 2:01PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Bad news for AstraZeneca is bad news for cruise stocks.

What happened

Shares of Norwegian Cruise Line Holdings (NCLH 0.67%), Carnival Corporation (CCL), and Royal Caribbean Cruises (RCL 0.57%) -- the three horsemen of the cruise industry apocalypse -- stumbled lower in afternoon trading Wednesday. As of 12:30 p.m. EDT, Norwegian stock is down 3.7%, Carnival 3.2%, and Royal Caribbean 2.2%.

So what

Why are these stocks down? Not because of any cruise industry news, certainly. In fact, the latest news out of cruise land is of the positive sort -- Carnival subsidiary Cunard announced that it has begun selling tickets for a 2022 "World Voyage" aboard the Queen Mary 2 sailing out of New York City.  

Instead, I suspect that cruise industry investors owe their woe today to news of a different sort.

Yesterday after close of trading, pharmaceutical company AstraZeneca reported that it has paused its phase 3 clinical trial of its AZD1222 COVID-19 vaccine to give it time to review safety data tied to a patient who has apparently suffered an adverse reaction.  

Collage showing a cruise ship, a man in a face mask and a microbe

Image source: Getty Images.

Now what

Commenting on AstraZeneca's move, which was first reported in the Stat medical journal last night, J.P. Morgan yesterday urged investors not to "over-interpret the impact of this afternoon's news," saying that a single patient falling ill -- which might not be tied to the vaccine -- is no reason to panic and is likely to have only an "extremely limited" impact on the race to find a safe vaccine against the coronavirus.    

Stat, however, noted that "the finding is having an impact on other AstraZeneca vaccine trials under way — as well as on the clinical trials being conducted by other vaccine manufacturers." And J.P. Morgan itself warned that the real risk here is that news of the illness "could damage the public perception of vaccine safety."

That's the news that's of real import to cruise investors today: The sooner a vaccine is discovered, tested, and distributed, the sooner it will be safe to cruise again and the sooner the CDC can be expected to lift its broad no-sail order on cruise ships sailing from American ports. Anything that "damages the public perception of vaccine safety," however, can be expected to delay that happy day.

And this, in a nutshell, is why cruise stocks are going down today.

Rich Smith has no position in any of the stocks mentioned. The Motley Fool recommends Carnival. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Royal Caribbean Stock Quote
Royal Caribbean
$59.68 (0.57%) $0.34
Carnival Stock Quote
$9.73 (%)
Norwegian Cruise Line Holdings Stock Quote
Norwegian Cruise Line Holdings
$16.43 (0.67%) $0.11

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.